Veltuzumab

Drug Profile

Veltuzumab

Alternative Names: Anti-CD20 monoclonal antibody - Immunomedics; hA20; Humanised anti-CD20 monoclonal antibody; IMMU-106; Monoclonal antibody hA20; Monoclonal antibody IMMU-106; Veltucyn

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator Immunomedics
  • Developer Immunomedics; Weill Cornell Medical College
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune thrombocytopenic purpura; Pemphigus; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Immune thrombocytopenic purpura; Non-Hodgkin's lymphoma
  • Phase I/II Follicular lymphoma
  • No development reported Chronic lymphocytic leukaemia
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 01 Apr 2017 Immunomedics terminates a phase I/II trial due to slow patient accrual in Follicular lymphoma (Combination therapy, First-line therapy) in USA (IV) (NCT01147393)
  • 15 Dec 2016 Biomarkers information updated
  • 03 Jun 2016 Phase-II clinical trials in Immune thrombocytopenic purpura in USA (SC) (Immunomedics pipeline, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top